To evaluate the rationale supporting the role of local treatment in the management of patients with metastatic prostate cancer (PCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Not all patients with metastatic PCa share the same prognosis, in which selected individuals with oligometastatic PCa might benefit from local therapies. These men would harbor a biologically different disease as compared with their counterparts with widespread metastases. Local treatment would eliminate the source of tumor-promoting factors, destroy the origin of metastatic cells, and stop the self-seeding process. Moreover, decreasing tumor burden would eventually allow for an improved response to systemic therapies. Recent clinical studies support an oncologic role of surgery or radiotherapy in metastatic PCa. However, their retrospective nature limits the relevance of these findings. Results of ongoing trials assessing the impact of local treatment in metastatic patients are needed to comprehensively address its role.
Preclinical observations provide a rationale for treatment of the primary tumor in selected patients with metastatic PCa. However, available clinical evidence comes from retrospective investigations, and only results of ongoing randomized trials would clarify the role of local treatment in the metastatic setting.
Current opinion in supportive and palliative care. 2016 Jun 18 [Epub ahead of print]
Giorgio Gandaglia, Nicola Fossati, Paolo Dell'Oglio, Marco Moschini, Vito Cucchiara, Nazareno Suardi, Alexandre Mottrie, Vincenzo Mirone, Francesco Montorsi, Alberto Briganti
aDivision of Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy bVita-Salute San Raffaele University, Milan, Italy cOLV Vattikuti Robotic Surgery Institute, Melle, Belgium dUrology Department, University of Naples Federico II, Naples, Italy.